News and Press Releases
Research | Drug Pipeline | Clinical Trials Positive Late Stage Study Results for Next-Generation, Triple-Combination Modulator

Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.

| 3 min read
Research Cystic Fibrosis Foundation Commits $100 Million to Infection Research

Funding will support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.

| 4 min read
Research FDA Approves Kalydeco® for Children With CF Ages 1 to 2

Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.

| 3 min read
Research | CFTR Modulators | Drug Pipeline FDA Expands Use of Orkambi® to Children With CF Ages 2 to 5

The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.

| 3 min read
Research | Drug Pipeline Drug Shows Promise in Reducing Inflammation in People With Cystic Fibrosis

Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.

| 2 min read